Watson Acquires Arrow in Bid for International Expansion
Taskin Ahmed
Abstract
Watson Pharmaceuticals is to acquire the generic drug company, Arrow Group, for US$ 1.75 B in a bid to expand beyond the US. By doing so it also acquired US rights to the generic version of the world’s leading cholesterol lowering drug, Lipitor® (atorvastatin).
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.